A triple-threat iron supplement that also improves gut health
Iron-deficiency anemia is a common condition marked by tiredness, headaches or ice cravings. But the oral iron supplements used to treat it can leave behind excess iron that… read more.
Iron-deficiency anemia is a common condition marked by tiredness, headaches or ice cravings. But the oral iron supplements used to treat it can leave behind excess iron that… read more.
New data from Eli Lilly and Company showed Omvoh (mirikizumab-mrkz) is the first and only interleukin-23p19 (IL-23p19) to help patients with moderately to severely active ulcerative colitis (UC)… read more.
A new study, led by experts at the University of Nottingham, has found that combining certain types of dietary supplements is more effective than single prebiotics or omega-3… read more.
Johnson & Johnson announced new 48-week data from the Phase III ASTRO study evaluating Tremfya (guselkumab) subcutaneous (SC) induction and maintenance therapy in adults with moderately to severely… read more.
Abivax SA announced the presentation of a second late breaking abstract for its lead drug candidate, obefazimod, for the treatment of moderately to severely active ulcerative colitis (UC)… read more.
NICE(UK): Guselkumab can be used as an option for previously treated moderately to severely active Crohn’s disease in adults, when: i) conventional or biological treatment: a) has not… read more.
NICE (UK): Guselkumab can be used as an option for treating moderately to severely active ulcerative colitis in adults when: i) a conventional treatment, biological treatment or Janus… read more.
A molecule made by bacteria in the gut can hitch a ride to the kidneys, where it sets off a chain reaction of inflammation, scarring and fibrosis —… read more.
UC Davis Health researchers have discovered that a natural molecule made by gut bacteria can reverse liver damage and repair the gut lining after aflatoxin exposure. The treatment may offer… read more.
The introduction of artificial intelligence (AI) to assist colonoscopies is linked to a reduction in the ability of endoscopists (health professionals who perform colonoscopies) to detect precancerous growths… read more.
The first patient has been dosed in the DESTINY-Gastric05 phase IIII trial evaluating Enhertu (trastuzumab deruxtecan) in combination with a fluoropyrimidine chemotherapy (5-FU or capecitabine) and Merck’s anti-PD-1… read more.
OPKO Health, Inc and Entera Bio Ltd announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has been selected for a poster presentation… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.